Evidence map›Paper›PMID 38223578›Full record

SynthesisAfrican health sciences2023

Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials.

Yao Jie, Lei Youchun, Chen Jingxiang

Open access · diamondAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in African health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yao JieDepartment of Gastroenterology ,The Sixth People's Hospital of Chongqing.
Lei YouchunDepartment of Gastroenterology ,The Sixth People's Hospital of Chongqing.
Chen JingxiangDepartment of Hepatobiliary Pancreatic Surgery, Chongqing Ninth People's Hospital.
The Sixth People's Hospital of Shenyang · CNFirst People's Hospital of Chongqing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The efficacy of emricasan for liver cirrhosis remains controversial. We conduct a systematic review and meta-analysis to explore the influence of emricasan versus placebo on the treatment of liver cirrhosis. Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through August 2021 and included randomized controlled trials (RCTs) assessing the efficacy of emricasan versus placebo for liver cirrhosis. This meta-analysis was performed using the random-effect model. Results: Four RCTs were included in the meta-analysis. Overall, compared with control group for liver cirrhosis, emricasan treatment had no substantial impact on MELD (SMD=-0.19; 95% CI=-0.44 to 0.06; P=0.14), INR (SMD=0.12; 95% CI=-0.13 to 0.37; P=0.36), total bilirubin (SMD=-0.27; 95% CI=-0.56 to 0.01; P=0.06), serum albumin (SMD=0; 95% CI=-0.25 to 0.25; P=1.00) or adverse events (OR=1.35; 95% CI=0.56 to 3.24; P=0.50). Conclusions: Emricasan treatment provided no benefit for the treatment of liver cirrhosis.

Indexed as

Liver CirrhosisPentanoic AcidsHumansRandomized Controlled Trials as Topic3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acidPentanoic AcidsEmricasanliver cirrhosismeta-analysisrandomized controlled trials

Identifiers

PMID38223578
PMCPMC10782287
OpenAlexW4387584848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.